Multicentric outcome analysis of XXXX -based immunosuppression in 252 liver transplant recipients.

@entity1 @entity1674 @entity9909 @entity3446 @entity86 @entity547 @entity715
SUMMARY: The use of @entity3446 (SRL) in orthotopic liver transplantation (OLT) has been controversial after experimental data suggested an increased risk of @entity715 ( @entity715 ). To assess the safety and efficacy of SRL as de novo immunosuppression in OLT recipients. Outcomes of 252 OLT @entity1 who received SRL were compared with outcomes of 291 OLT recipients who received @entity9909 in a retrospective study. Primary outcomes of this study were: @entity1 - and graft survivals, vascular, biliary, wound complications and rejection rates. Secondary outcomes were: @entity86 rate, bone marrow and renal function and changes of lipid levels. @entity1 - and graft survivals, rejection and infection rates were similar. In the SRL group, @entity715 occurred in 1.2%, biliary complications in 19.4%, and incisional hernias in 9.1%. In the control group the incidence of @entity715 was 5.8% (P = 0.004), biliary complications 18.5% (P = NS) and @entity547 .2% (P = NS). @entity1 on SRL experienced significantly higher levels of serum @entity1674 but fewer acute cellular rejections. Bone marrow and renal functions were similar in both the groups. Our findings would suggest that SRL is safe and effective for very selected OLT recipients. Randomized controlled trials are necessary to confirm our results.
